OTC · ENZN
Viskase Companies, Inc.
$4.71+$0.06 (+1.29%)
Viskase Companies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.06% below the high.
Loading market information…
OTC · FNAM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evolutionary Genomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evolutionary Genomics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. The company is based in Castle Rock, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:50 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.71+$0.06 (+1.29%)
Viskase Companies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.06% below the high.
$1.94+$0.02 (+0.78%)
HealthLynked Corp.’s quoted price sits in the lower half of its reported 52-week range, 70.15% below the high.
$0.06$0.00 (0.0%)
Reflect Scientific, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.24% below the high.
CA$0.05CA$0.00 (0.0%)
Telo Genomics Corp.’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
$0.11$0.00 (0.0%)
LFTD Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
CA$0.09-CA$0.02 (-15.0%)
Doseology Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.5% below the high.
$0.00$0.00 (0.0%)
Sorrento Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.12% below the high.
$0.03-$0.00 (-7.33%)
Sigyn Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.61% below the high.
